Lisa

Haematology Registrar
MRCP (UK), MBBCh, BSc (Hons), PGCert Transformative Oncology
Avid LFC supporter

[Lisa @lisijeff]

Y wal Goch, Cymru am byth 🏴󠁧󠁢󠁷󠁬󠁳󠁿

[Wales 🏴󠁧󠁢󠁷󠁬󠁳󠁿 @Cymru]

Ry'n ni yma o hyd, er gwaetha pawb a phopeth.
Er dued yw'r fagddu o'n cwmpas, ry'n ni'n barod am doriad y wawr!

#ArBenYByd | #TogetherStronger | #YWalGoch

[Lisa @lisijeff]

@EastMidRailway your 13:02 from liverpool southparkway to nottingham is absolutely horrific conditions. But your train conductor is absolutely amazing considering the working conditions you have given him

[Graham Collins @graham74GC]

Townsend - real world bispecific antibody UK data, 3L+ DLBCL
• whole cohort 40% ORR and 24% CMR
• in trial eligible pts, CMR > 40% which is encouraging.
• pt selection crucial - better with lower PS & if receive 2 cycles
• PFS worse if prior benda < 6mo

#EHA2026

[Toby Eyre @tobyeyre82]

Important B-cell news!

[Joshua Zeidner MD @LeukDocJZ]

Huge congratulations to Amir Fathi for delivering one of the most impactful plenary presentations @ASH_hematology in AML in past decade. The PARADIGM study may lead to a Paradigm shift- Aza/Ven > intensive chemo in newly Dx high-risk AML. 👏👏👏

[Lisa @lisijeff]

Falchi et al present staggering results of EPCORE FL-1 study R2+ Epcoritamab vs R2 alone!

[Lisa @lisijeff]

Next Reid Merryman presents multicentre phase 2 trial of Rituximab (as cytoreduction) + Epcoras 1L for high tumor burden FL 1y PFS 97% , no G2 CRS in those receiving 3 step up doses of Epcor. Interedting Qs how much of this imrpoved CRS is ritux how much is extra step up dosing?

[Lisa @lisijeff]

Falchi et al presenting MITHIC FL2 trial Mosunetuzumab + Zanubrutinib ORR 92%, median f/u 6.5 months. Good safety profile, no G3 CRS. Hypothesising addition of BTKi mitigating ?reversing T cell exhaustion which is key to bispecific resistance. Great start to my day 2 at ASH!

[Graham Collins @graham74GC]

An oft neglected lymphoma subtype. Management remains controversial so come and hear the latest.

[Graham Collins @graham74GC]

Wurm-Kuczera: R-pola-glo in unfit 1L DLBCL. Anthacycline ineligible ‘Ix discretion’
• glofit, pola, ritux. Fixed duration
• EOT: 90% ORR & 81% CMR
• 4% ICANs, G3+ CRS 2.5%
V impressive responses. Need to see survival endpoints.
#18ICML #ICML25 #lymsm

[Lisa @lisijeff]

👏🏻🩸

[William Aird @WilliamAird4]

Did you know that a red cell:

1. Travels at ~4.8–6.3 km/h (walking speed) on average, with bursts up to 15 inches/second in the aorta

2. Completes a full circulation cycle in ~60 seconds

3. Completes ~172,800 loops and travels ~300 miles during its 120-day lifespan

[Stefano Luminari, MD @StefanoLuminari]

2025 edition of the Cantera just started in Lyon…20 rising stars in the lymphoma field coached by a great coach Gilles Salles @EHA_Hematology @filonlus #lymsm

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Mostafa Faisal @MostafaFaisal14]

Relapsed/Refractory Follicular Lymphoma: Current Advances and Emerging Perspectives
https://t.co/YJ1QkTAdPU

[Lisa @lisijeff]

Slowly trying to transition to Bluesky as ethically struggling with X. Follow: https://t.co/DV42wtVwha :)!

[Lisa @lisijeff]

@GaryLineker @RestIsFootball @MicahRichards @alanshearer If you could bring anyone else as a permanent fixture to the pod who would it be (dead or alive)?

[Resident Doctors @BMAResidents]

Competition ratios are terrible.

Your UKRDC passed the following policy:

"This committee resolves to prioritise lobbying for a method of UK graduate prioritisation for speciality training applications and on the issue of training bottlenecks during this session." (1/2)

[Toby Eyre @tobyeyre82]

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma | Journal of Clinical Oncology https://t.co/HfLB7dCyER

[Lisa @lisijeff]

Great to see @BloodCancer_Res @bloodcancer_uk involvement and an exciting programme today for the UK LYMPHOMA RESEARCH GROUP update

[Graham Collins @graham74GC]

The UK Lymphoma Research group has faced its challenges with the demise of the NCRI. Huge progress made however with very active groups delivering important studies. A bright future for 🇬🇧 lymphoma research. @HT_Medical

[Lisa @lisijeff]

Extremely promising data from OASIS ll

[Toby Eyre @tobyeyre82]

First Interim results
OASIS II
1L non-chemo #MCL RCT
2Y Fixed duration Arm A CD20+Ibr vs Arm B CD20+I+V
6m MRD primary end pt
6m uMRD 53.8% Arm A vs 82.1% Arm B
CMR at C6 54% Arm A vs 69% Arm B
median fup 13.5m
1y PFS 91%+OS 95%
Part II now recruited: lots more to come! #ASH24

[Toby Eyre @tobyeyre82]

ENRICH Primary analysis
4y fup
R-Ibrutinib vs R-chemo (BR or RCHOP) 1L #MCL
IR superior PFS to ICT HR 0.69 p=0.003
⬇️ haem tox
Earlier ⬆️QoL with R-Ibr
Major benefit seen vs RCHOP subgrp
1st 1L RCT across any lymphoma (not incl CLL) showing non-chemo superior to ICT
#ASH2024